Media stories about PTC Therapeutics (NASDAQ:PTCT) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PTC Therapeutics earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.2710430149446 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
PTCT has been the topic of a number of recent analyst reports. Cowen reissued a “hold” rating on shares of PTC Therapeutics in a report on Wednesday, October 25th. Zacks Investment Research raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a report on Thursday, January 4th. Bank of America lowered shares of PTC Therapeutics from a “neutral” rating to an “underperform” rating in a report on Thursday, October 26th. ValuEngine raised shares of PTC Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, JPMorgan Chase & Co. raised their price target on shares of PTC Therapeutics to $15.00 and gave the stock a “neutral” rating in a report on Friday, November 24th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $19.57.
Shares of PTC Therapeutics (NASDAQ PTCT) traded down $0.24 during trading on Friday, reaching $22.99. 864,636 shares of the company’s stock were exchanged, compared to its average volume of 1,031,745. The company has a market cap of $953.86, a price-to-earnings ratio of -7.95 and a beta of 1.73. PTC Therapeutics has a 1-year low of $8.12 and a 1-year high of $28.75. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.97 and a current ratio of 3.08.
In other news, CEO Stuart Walter Peltz sold 2,230 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $18.03, for a total value of $40,206.90. Following the completion of the sale, the chief executive officer now directly owns 26,646 shares of the company’s stock, valued at approximately $480,427.38. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders sold 2,719 shares of company stock worth $48,848. Insiders own 8.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “PTC Therapeutics (PTCT) Earns Daily News Impact Rating of 0.14” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/11/ptc-therapeutics-ptct-earns-daily-news-impact-rating-of-0-14.html.
About PTC Therapeutics
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.